Home Cart Sign in  
Chemical Structure| 13676-47-6 Chemical Structure| 13676-47-6

Structure of 13676-47-6

Chemical Structure| 13676-47-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 13676-47-6 ]

CAS No. :13676-47-6
Formula : C13H11N3O
M.W : 225.25
SMILES Code : NC1=CC=C(OC(C2=CC=C(N)C=C2)=N3)C3=C1
MDL No. :MFCD00445970
InChI Key :UMGYJGHIMRFYSP-UHFFFAOYSA-N
Pubchem ID :614385

Safety of [ 13676-47-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 13676-47-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 17
Num. arom. heavy atoms 15
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 68.25
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

78.07 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.83
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.31
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.68
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.62
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.95
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.08

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.28
Solubility 0.119 mg/ml ; 0.000526 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.59
Solubility 0.0582 mg/ml ; 0.000258 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.72
Solubility 0.00428 mg/ml ; 0.000019 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.03 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.67

Application In Synthesis of [ 13676-47-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 13676-47-6 ]

[ 13676-47-6 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 13676-47-6 ]
  • [ 26638-43-7 ]
  • methyl 2-(N-(4-(5-((2-(methoxycarbonyl)phenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)sulfamoyl)benzoate [ No CAS ]
YieldReaction ConditionsOperation in experiment
45% With pyridine; In dichloromethane; at 20℃; for 18h; General procedure: To a stirring mixture of 5-amino-2-(4-aminophenyl) benzoxazole (1 eq.) in anhydrous CH2Cl2 (5 mL) was added the respective sulfonyl chloride (2.1 eq.) followed by anhydrous pyridine (2.1 eq.). The reaction was allowed to stir at room temperature for 18 h and was then chromatographed over silica and concentrated. If necessary, the product was further purified by preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and lyophilized.
  • 2
  • [ 13676-47-6 ]
  • [ 26638-43-7 ]
  • 2-(N-(4-(5-((2-carboxyphenyl)sulfonamido)benzo[d]oxazol-2-yl)phenyl)sulfamoyl)benzoic acid [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 13676-47-6 ]

Aryls

Chemical Structure| 1367920-70-4

A292265 [1367920-70-4]

(2-Phenylbenzo[d]oxazol-6-yl)methanamine

Similarity: 0.95

Chemical Structure| 440122-66-7

A197635 [440122-66-7]

7-Bromo-2-(4-hydroxyphenyl)benzo[d]oxazol-5-ol

Similarity: 0.87

Chemical Structure| 16707-41-8

A120052 [16707-41-8]

1-(4-(Benzo[d]oxazol-2-yl)phenyl)-1H-pyrrole-2,5-dione

Similarity: 0.82

Chemical Structure| 95331-56-9

A142226 [95331-56-9]

4-(Oxazolo[4,5-b]pyridin-2-yl)aniline

Similarity: 0.79

Chemical Structure| 861673-68-9

A176100 [861673-68-9]

2-(2-(tert-Butyl)phenoxy)pyridin-3-amine

Similarity: 0.78

Amines

Chemical Structure| 1367920-70-4

A292265 [1367920-70-4]

(2-Phenylbenzo[d]oxazol-6-yl)methanamine

Similarity: 0.95

Chemical Structure| 95331-56-9

A142226 [95331-56-9]

4-(Oxazolo[4,5-b]pyridin-2-yl)aniline

Similarity: 0.79

Chemical Structure| 861673-68-9

A176100 [861673-68-9]

2-(2-(tert-Butyl)phenoxy)pyridin-3-amine

Similarity: 0.78

Chemical Structure| 70627-52-0

A130033 [70627-52-0]

N-(4-(Benzyloxy)benzylidene)-4-fluoroaniline

Similarity: 0.71

Chemical Structure| 21203-83-8

A451015 [21203-83-8]

2-Phenoxypyridin-4-amine

Similarity: 0.70

Related Parent Nucleus of
[ 13676-47-6 ]

Benzoxazoles

Chemical Structure| 1367920-70-4

A292265 [1367920-70-4]

(2-Phenylbenzo[d]oxazol-6-yl)methanamine

Similarity: 0.95

Chemical Structure| 136663-38-2

A302357 [136663-38-2]

(2-Methylbenzo[d]oxazol-5-yl)methanol

Similarity: 0.88

Chemical Structure| 440122-66-7

A197635 [440122-66-7]

7-Bromo-2-(4-hydroxyphenyl)benzo[d]oxazol-5-ol

Similarity: 0.87

Chemical Structure| 6797-13-3

A114719 [6797-13-3]

2-Ethylbenzo[d]oxazole

Similarity: 0.85

Chemical Structure| 16707-41-8

A120052 [16707-41-8]

1-(4-(Benzo[d]oxazol-2-yl)phenyl)-1H-pyrrole-2,5-dione

Similarity: 0.82